Trial Profile
A Randomized Phase 3 Study of Tasisulam-sodium Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle Versus Paclitaxel as Second-line Treatment in Patients With Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Tasisulam (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms SUMMIT-1
- Sponsors Eli Lilly and Company
- 07 Oct 2021 This trial has been completed in France (global end of the trial 2011-03-18 ) as per European Clinical Trials Database.
- 26 Mar 2014 Results published in the Cancer.
- 16 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.